AI Engines For more Details: Perplexity Kagi Labs You
Retinoid Derivative: Acitretin is a synthetic retinoid derivative of vitamin A (retinol) that modulates cellular differentiation, proliferation, and inflammation in the skin. It exerts its therapeutic effects by binding to nuclear receptors and regulating gene expression involved in keratinocyte differentiation and epidermal turnover.
Treatment of Psoriasis: Acitretin is indicated for the treatment of severe psoriasis, including plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis, which are resistant to or not adequately controlled by other therapies. It helps reduce the severity and extent of psoriatic lesions, alleviate symptoms such as scaling and itching, and improve overall quality of life.
Psoriatic Arthritis: Acitretin may also be used as an adjunctive therapy in the management of psoriatic arthritis, a chronic inflammatory arthritis associated with psoriasis. While acitretin primarily targets cutaneous manifestations of psoriasis, it may provide additional benefits in patients with psoriatic arthritis by reducing skin involvement and inflammation.
Mechanism of Action: The exact mechanism of action of acitretin in psoriasis is not fully understood, but it is thought to involve normalization of abnormal keratinocyte proliferation and differentiation, suppression of inflammatory cytokines, and modulation of immune responses in the skin.
Long-term Therapy: Acitretin is typically used as a long-term therapy for psoriasis, often in combination with other treatments such as topical corticosteroids, phototherapy (UVB or PUVA), or biologic agents. Long-term maintenance therapy with acitretin may help control psoriatic symptoms and prevent disease relapse.
Dosage and Administration: Acitretin is administered orally in the form of capsules. The dosage and duration of treatment depend on the severity of the psoriasis, individual patient response, and tolerability. It is usually initiated at a low dose and titrated gradually to achieve optimal therapeutic effects while minimizing side effects.
Side Effects: Common side effects of acitretin may include dry skin, cheilitis (inflammation of the lips), pruritus (itching), hair loss, and photosensitivity (increased sensitivity to sunlight). Other potential side effects may include mucocutaneous effects (e.g., conjunctivitis, dry eyes), hepatotoxicity (liver damage), hyperlipidemia (elevated lipid levels), and teratogenicity (birth defects).
Contraindications and Precautions: Acitretin is contraindicated in pregnant women or women of childbearing potential due to its teratogenic effects. Female patients of childbearing age must use effective contraception before, during, and for at least three years after discontinuing acitretin therapy. It is also contraindicated in patients with severe hepatic or renal impairment.
Monitoring: Patients receiving acitretin therapy require regular monitoring of liver function tests, lipid levels, and signs of adverse effects such as mucocutaneous symptoms or mood changes. Monitoring is particularly important during long-term treatment to detect and manage potential side effects.
Discontinuation and Withdrawal: Acitretin therapy should be discontinued gradually, and patients should be monitored for potential rebound flare-ups of psoriasis or exacerbation of symptoms upon discontinuation. A washout period may be necessary before starting alternative therapies, especially in patients switching to medications with overlapping toxicities.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.1 | -0.1 | |
| ADHD | 3.3 | 0.1 | 32 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.4 | 0 |
| Allergic Rhinitis (Hay Fever) | 1.9 | 0.6 | 2.17 |
| Allergies | 3.6 | 2.2 | 0.64 |
| Allergy to milk products | 1.7 | 0.8 | 1.13 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 1.9 | 4.7 | -1.47 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 1.2 | 0.33 |
| Ankylosing spondylitis | 3.2 | 1.2 | 1.67 |
| Anorexia Nervosa | 0.4 | 2.3 | -4.75 |
| Antiphospholipid syndrome (APS) | 1.6 | 1.6 | |
| Asthma | 0.6 | 0.9 | -0.5 |
| Atherosclerosis | 1 | 2.4 | -1.4 |
| Atrial fibrillation | 2.3 | 1.3 | 0.77 |
| Autism | 8.3 | 6 | 0.38 |
| Barrett esophagus cancer | 0.1 | 0.2 | -1 |
| benign prostatic hyperplasia | 0.3 | 0.3 | |
| Bipolar Disorder | 1.3 | 1.1 | 0.18 |
| Brain Trauma | 0.5 | 0.6 | -0.2 |
| Carcinoma | 2.7 | 2.2 | 0.23 |
| Celiac Disease | 1.9 | 2.2 | -0.16 |
| Cerebral Palsy | 1 | 1.4 | -0.4 |
| Chronic Fatigue Syndrome | 3.7 | 4.3 | -0.16 |
| Chronic Kidney Disease | 2.2 | 1.8 | 0.22 |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.5 | 1.2 |
| Chronic Urticaria (Hives) | 1.6 | 1 | 0.6 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1.4 | 0 |
| Colorectal Cancer | 3.6 | 0.9 | 3 |
| Constipation | 1 | 0.8 | 0.25 |
| Coronary artery disease | 1.8 | 0.6 | 2 |
| COVID-19 | 7.2 | 9.8 | -0.36 |
| Crohn's Disease | 5.3 | 4.1 | 0.29 |
| cystic fibrosis | 0.9 | 0.7 | 0.29 |
| deep vein thrombosis | 0.9 | 1.1 | -0.22 |
| Depression | 6.6 | 7.3 | -0.11 |
| Dermatomyositis | 0.2 | 0.1 | 1 |
| Eczema | 1 | 1.6 | -0.6 |
| Endometriosis | 2.2 | 0.9 | 1.44 |
| Eosinophilic Esophagitis | 0.1 | -0.1 | |
| Epilepsy | 2.1 | 2 | 0.05 |
| Fibromyalgia | 2.4 | 1.4 | 0.71 |
| Functional constipation / chronic idiopathic constipation | 5.1 | 3.2 | 0.59 |
| gallstone disease (gsd) | 2 | 0.5 | 3 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.9 | 0.22 |
| Generalized anxiety disorder | 1.8 | 1.1 | 0.64 |
| giant cell arteritis | 0.4 | -0.4 | |
| Glioblastoma | 0.2 | -0.2 | |
| Gout | 0.1 | -0.1 | |
| Graves' disease | 1.1 | 1.2 | -0.09 |
| Halitosis | 0.3 | 0.2 | 0.5 |
| Hashimoto's thyroiditis | 2 | 0.3 | 5.67 |
| Hidradenitis Suppurativa | 0.2 | 0.1 | 1 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.3 | 1.1 | 1.09 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.2 | 3 |
| hyperglycemia | 0.3 | 1.3 | -3.33 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.4 | 0.5 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.1 | 2.6 | -0.24 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 2.3 | -2.3 | |
| Inflammatory Bowel Disease | 3.4 | 8 | -1.35 |
| Insomnia | 0.8 | 0.6 | 0.33 |
| Intelligence | 0.6 | 0.4 | 0.5 |
| Intracranial aneurysms | 1.4 | 0.4 | 2.5 |
| Irritable Bowel Syndrome | 3.2 | 2.6 | 0.23 |
| Liver Cirrhosis | 3.5 | 2.2 | 0.59 |
| Long COVID | 5.3 | 6.1 | -0.15 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.6 | 1 | -0.67 |
| ME/CFS with IBS | 1.2 | 1.3 | -0.08 |
| ME/CFS without IBS | 1.3 | 1.1 | 0.18 |
| Menopause | 1.2 | 1.2 | |
| Metabolic Syndrome | 6.5 | 4.8 | 0.35 |
| Mood Disorders | 8.9 | 7.3 | 0.22 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.4 | 1.25 |
| Multiple Sclerosis | 2.8 | 5.4 | -0.93 |
| Multiple system atrophy (MSA) | 0.7 | 0.9 | -0.29 |
| Neuropathy (all types) | 0.7 | 0.3 | 1.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 3.8 | -0.81 |
| NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
| Obesity | 6.6 | 3.5 | 0.89 |
| obsessive-compulsive disorder | 5.9 | 3.5 | 0.69 |
| Osteoarthritis | 1.9 | 0.5 | 2.8 |
| Osteoporosis | 1.5 | 0.8 | 0.88 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 2.1 | 3.6 | -0.71 |
| Polycystic ovary syndrome | 2.6 | 2.3 | 0.13 |
| Postural orthostatic tachycardia syndrome | 0.4 | 0.3 | 0.33 |
| Premenstrual dysphoric disorder | 0.9 | 0.4 | 1.25 |
| primary biliary cholangitis | 0.4 | -0.4 | |
| Psoriasis | 3.6 | 2.5 | 0.44 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.8 | 2.5 | 0.92 |
| Rosacea | 1.4 | 0.8 | 0.75 |
| Schizophrenia | 4.2 | 1.9 | 1.21 |
| scoliosis | 0.1 | 0.5 | -4 |
| Sjögren syndrome | 2.2 | 1.8 | 0.22 |
| Sleep Apnea | 1.1 | 1.1 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.2 | 3 |
| Stress / posttraumatic stress disorder | 2.2 | 1.4 | 0.57 |
| Systemic Lupus Erythematosus | 2.9 | 1.6 | 0.81 |
| Tic Disorder | 1.3 | 0.9 | 0.44 |
| Tourette syndrome | 0.1 | 0.2 | -1 |
| Type 1 Diabetes | 3.2 | 1.9 | 0.68 |
| Type 2 Diabetes | 6.6 | 4.6 | 0.43 |
| Ulcerative colitis | 2.4 | 3.9 | -0.63 |
| Unhealthy Ageing | 4.4 | 1.9 | 1.32 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.